Trial · NCT01998035
Participant flow192
How many started, completed or left each group, period by period.
41 to 60 of 192
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Phase 1: Dose Level 2 | NOT COMPLETED | Phase 1, Dose Level 1: Oral 5-Azacitidine 100 mg and Romidepsin 10 mg/m2 | 0 | |
| Phase 1: Dose Level 2 | NOT COMPLETED | Phase 1, Dose Level 2: Oral 5-Azacitidine 200 mg and Romidepsin 10 mg/m2 | 0 | |
| Phase 1: Dose Level 2 | NOT COMPLETED | Phase 1, Dose Level 3: Oral 5-Azacitidine 200 mg and Romidepsin 10 mg/m2 (Extended Cycle) | 0 | |
| Phase 1: Dose Level 2 | NOT COMPLETED | Phase 1, Dose Level 4: Oral 5-Azacitidine 300 mg and Romidepsin 10 mg/m2 | 0 | |
| Phase 1: Dose Level 2 | NOT COMPLETED | Phase 1, Dose Level 5: Oral 5-Azacitidine 300 mg and Romidepsin 14 mg/m2 | 0 | |
| Phase 1: Dose Level 2 | NOT COMPLETED | Phase 1, Dose Level 6: Oral 5-Azacitidine 300 mg and Romidepsin 14 mg/m2 | 0 | |
| Phase 1: Dose Level 2 | NOT COMPLETED | Phase 1, Dose Level 6 (MTD): Oral 5-Azacitidine 300 mg and Romidepsin 14 mg/m2 | 0 | |
| Phase 1: Dose Level 2 | NOT COMPLETED | Phase 2, MTD: Oral 5-Azacitidine 300 mg and Romidepsin 14 mg/m2 | 0 | |
| Phase 1: Dose Level 3 | STARTED | Phase 1, Dose Level 1: Oral 5-Azacitidine 100 mg and Romidepsin 10 mg/m2 | 0 | |
| Phase 1: Dose Level 3 | STARTED | Phase 1, Dose Level 2: Oral 5-Azacitidine 200 mg and Romidepsin 10 mg/m2 | 0 | |
| Phase 1: Dose Level 3 | STARTED | Phase 1, Dose Level 3: Oral 5-Azacitidine 200 mg and Romidepsin 10 mg/m2 (Extended Cycle) | 3 | |
| Phase 1: Dose Level 3 | STARTED | Phase 1, Dose Level 4: Oral 5-Azacitidine 300 mg and Romidepsin 10 mg/m2 | 0 | |
| Phase 1: Dose Level 3 | STARTED | Phase 1, Dose Level 5: Oral 5-Azacitidine 300 mg and Romidepsin 14 mg/m2 | 0 | |
| Phase 1: Dose Level 3 | STARTED | Phase 1, Dose Level 6: Oral 5-Azacitidine 300 mg and Romidepsin 14 mg/m2 | 0 | |
| Phase 1: Dose Level 3 | STARTED | Phase 1, Dose Level 6 (MTD): Oral 5-Azacitidine 300 mg and Romidepsin 14 mg/m2 | 0 | |
| Phase 1: Dose Level 3 | STARTED | Phase 2, MTD: Oral 5-Azacitidine 300 mg and Romidepsin 14 mg/m2 | 0 | |
| Phase 1: Dose Level 3 | COMPLETED | Phase 1, Dose Level 1: Oral 5-Azacitidine 100 mg and Romidepsin 10 mg/m2 | 0 | |
| Phase 1: Dose Level 3 | COMPLETED | Phase 1, Dose Level 2: Oral 5-Azacitidine 200 mg and Romidepsin 10 mg/m2 | 0 | |
| Phase 1: Dose Level 3 | COMPLETED | Phase 1, Dose Level 3: Oral 5-Azacitidine 200 mg and Romidepsin 10 mg/m2 (Extended Cycle) | 3 | |
| Phase 1: Dose Level 3 | COMPLETED | Phase 1, Dose Level 4: Oral 5-Azacitidine 300 mg and Romidepsin 10 mg/m2 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01998035/flow?page=3